208 related articles for article (PubMed ID: 8289856)
1. The treatment of multiple myeloma.
Alexanian R; Dimopoulos M
N Engl J Med; 1994 Feb; 330(7):484-9. PubMed ID: 8289856
[No Abstract] [Full Text] [Related]
2. Treatment of multiple myeloma: 2009 update.
Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
[TBL] [Abstract][Full Text] [Related]
3. Effective treatment of advanced multiple myeloma refractory to alkylating agents.
Barlogie B; Smith L; Alexanian R
N Engl J Med; 1984 May; 310(21):1353-6. PubMed ID: 6546971
[TBL] [Abstract][Full Text] [Related]
4. High dose dexamethasone as first line therapy of multiple myeloma? A case report.
Meregalli M; Bertola G; Grando D
Recenti Prog Med; 1998 Jan; 89(1):18-20. PubMed ID: 9549388
[TBL] [Abstract][Full Text] [Related]
5. [Recent progress in the treatment of hematological malignancies. V. Therapy of multiple myeloma].
Imamura Y
Nihon Naika Gakkai Zasshi; 1989 Jun; 78(6):809-13. PubMed ID: 2677178
[No Abstract] [Full Text] [Related]
6. Intensive therapy for myeloma.
McElwain TJ; Meldrum M; Gore ME; Millar BC; Malpas JS
Pathol Biol (Paris); 1990 Oct; 38(8):830. PubMed ID: 2274375
[No Abstract] [Full Text] [Related]
7. Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT.
Pitini V; Arrigo C; Aloi G; Micali C; La Gattuta G
Bone Marrow Transplant; 2003 Jun; 31(11):1065; author reply 1067. PubMed ID: 12774062
[No Abstract] [Full Text] [Related]
8. [Recent therapy for refractory myeloma].
Togawa A
Rinsho Ketsueki; 1993 Apr; 34(4):450-4. PubMed ID: 8510332
[TBL] [Abstract][Full Text] [Related]
9. [Monoclonal gammapathy of indeterminate origin and myeloma].
Bury J; Salmon J; Fillet G
Rev Med Liege; 1988 Apr; 43(8):270-4. PubMed ID: 3285431
[No Abstract] [Full Text] [Related]
10. [Improved prognosis of generalized AL-amyloidosis in a patient with multiple myeloma treated according to the VAD protocol].
Sarkisova IA; Rameev VV; Kozlovskaia LV; Andreeva NE
Ter Arkh; 2003; 75(8):81-2. PubMed ID: 14520860
[No Abstract] [Full Text] [Related]
11. Assessment of early paraprotein response to vincristine-doxorubicin-dexamethasone chemotherapy may help guide therapy in multiple myeloma.
Ross DM; To LB; Horvath N
Intern Med J; 2004; 34(9-10):576-8. PubMed ID: 15482273
[TBL] [Abstract][Full Text] [Related]
12. Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study.
Cavo M; Benni M; Ronconi S; Fiacchini M; Gozzetti A; Zamagni E; Cellini C; Tosi P; Baccarani M; Tura S;
Haematologica; 2002 Sep; 87(9):934-42. PubMed ID: 12217805
[TBL] [Abstract][Full Text] [Related]
13. Advances in the treatment of multiple myeloma.
Lokhorst HM; Dekker AW
Cancer Treat Rev; 1993 Apr; 19(2):113-28. PubMed ID: 7683253
[No Abstract] [Full Text] [Related]
14. [Combination chemotherapy (modified M-2 protocol) for multiple myeloma].
Iwata Y; Karitani Y; Tanaka I; Kobayashi T; Ohno T; Kageyama S; Katayama N; Kataoka Y; Kamio N; Ohota C
Rinsho Ketsueki; 1984 Sep; 25(9):1380-7. PubMed ID: 6549187
[No Abstract] [Full Text] [Related]
15. Therapy of multiple myeloma. Italian Multiple Myeloma Study Group.
Boccadoro M; Avvisati G; Cantonetti M; Cavo-Comotti BM; Frieri R; Gallamini A; Gallone G; Lauta VM; Liberati M; Marmont F
Pathol Biol (Paris); 1990 Oct; 38(8):829. PubMed ID: 2274374
[No Abstract] [Full Text] [Related]
16. [Results of combined treatment of advanced forms of multiple myeloma with vincristine, melphalan, cyclophosphamide and prednisone (VMCP) and with vincristine, doxorubicin, cyclophosphamide and prednisone (VDCP)].
Robak T; Krykowski E; Płuzańska A; Olszańska-Skorek T; Urbańska-Ryś H; Polkowska-Kulesza E; Błasińska-Morawiec M; Mazurowa A
Pol Tyg Lek; 1983 Apr; 38(16):481-4. PubMed ID: 6579509
[No Abstract] [Full Text] [Related]
17. Combination chemotherapy versus melphalan and prednisone in multiple myeloma.
Gruber A; Osby E
Chemioterapia; 1987 Jun; 6(2 Suppl):725-6. PubMed ID: 3509531
[No Abstract] [Full Text] [Related]
18. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.
Vogl DT; Liu SV; Chong EA; Luger SM; Porter DL; Schuster SJ; Tsai DE; Perl A; Loren AW; Goldstein SC; Nasta SD; Andreadis C; Mangan PA; Hummel K; Siegel DL; Glatstein E; Stadtmauer EA
Am J Hematol; 2007 Dec; 82(12):1071-5. PubMed ID: 17696204
[TBL] [Abstract][Full Text] [Related]
19. [Acute and chronic renal failure in patients with myeloma].
Biriukova LS; Volodiaeva EB; Fetisova EV; Pivnik AV; Margolin OV
Ter Arkh; 1999; 71(7):58-64. PubMed ID: 10481869
[TBL] [Abstract][Full Text] [Related]
20. VAMP followed by high dose melphalan and autologous bone marrow transplantation for multiple myeloma.
McElwain TJ; Gore ME; Meldrum M; Viner C; Judson IR; Malpas JS
Bone Marrow Transplant; 1989 Dec; 4 Suppl 4():109-12. PubMed ID: 2697419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
